Get the Stockscreener App
0.572
0.07%
0.0004
After Hours:
.57
-0.002
-0.35%
Quoin Pharmaceuticals Ltd Adr stock is traded at $0.572, with a volume of 217.23K.
It is up +0.07% in the last 24 hours and down -13.60% over the past month.
Quoin Pharmaceuticals Ltd is a clinical stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. Its pipeline comprises three products that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Epidermolysis Bullosa, and others.
See More
Previous Close:
$0.5716
Open:
$0.609
24h Volume:
217.23K
Relative Volume:
0.07
Market Cap:
$4.68M
Revenue:
-
Net Income/Loss:
$-8.28M
P/E Ratio:
-0.1029
EPS:
-5.56
Net Cash Flow:
$-7.99M
1W Performance:
-13.33%
1M Performance:
-13.60%
6M Performance:
-12.80%
1Y Performance:
-87.12%
1-Day Range:
$0.5653
$0.609
1-Week Range:
$0.5636
$0.6548
52-Week Range:
$0.425
$6.18
Quoin Pharmaceuticals Ltd Adr Stock (QNRX) Company Profile
Name
Quoin Pharmaceuticals Ltd Adr
Sector
Industry
Phone
97299741444
Address
23 HATA'AS STREET, KFAR SABA
Compare QNRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
QNRX
Quoin Pharmaceuticals Ltd Adr
|
0.572 | 4.68M | 0 | -8.28M | -7.99M | -5.56 |
|
VRTX
Vertex Pharmaceuticals Inc
|
411.66 | 106.01B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
690.87 | 75.92B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
665.60 | 39.80B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
240.51 | 31.02B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
112.43 | 26.95B | 3.30B | -501.07M | 1.03B | -2.1146 |
Quoin Pharmaceuticals Ltd Adr Stock (QNRX) Latest News
Quoin reports progress in pediatric skin disorder study - Investing.com
PRISM MarketView Spotlights Quoin Pharmaceuticals CEO Dr. Michael Myers as Specialty Pharma Shares News of Highly Positive Interim Data in Most Advanced, Comprehensive Netherton Syndrome Trials - GlobeNewswire Inc.
Quoin Pharmaceuticals reports positive trial results for skin treatment - Investing.com
Quoin reports positive results in Netherton Syndrome study - Investing.com
Quoin Pharmaceuticals CFO Dunn Gordon buys $54,999 in shares - Investing.com India
Quoin Pharmaceuticals CEO Michael Myers acquires $250,000 in shares By Investing.com - Investing.com South Africa
Quoin Pharmaceuticals director Anthony Culverwell buys $45,000 in shares - Investing.com India
Quoin Pharmaceuticals COO Denise Carter buys $250,000 in shares - Investing.com India
Quoin Pharmaceuticals COO Denise Carter buys $250,000 in shares By Investing.com - Investing.com South Africa
Quoin Pharmaceuticals director Anthony Culverwell buys $45,000 in shares By Investing.com - Investing.com South Africa
Quoin Pharmaceuticals CFO Dunn Gordon buys $54,999 in shares By Investing.com - Investing.com South Africa
Quoin Pharmaceuticals sets terms for public offering - Investing.com
Quoin Pharmaceuticals advances Netherton Syndrome study - Investing.com India
Quoin Pharmaceuticals amends shareholder rights, adjusts executive compensation - Investing.com India
Quoin Pharmaceuticals Provides Corporate Update and Announces Third Quarter 2024 Financial Results - Yahoo Finance
Quoin Pharmaceuticals advances Netherton syndrome treatment trial - Investing.com
Quoin Pharmaceuticals granted extension to meet Nasdaq listing - Investing.com India
Quoin Pharmaceuticals expands UK clinical trials for rare disease - Investing.com
Quoin Pharmaceuticals sets date for 2024 shareholder meeting - Investing.com
Balance Sheet Insights: Quoin Pharmaceuticals Ltd ADR (QNRX)’s Debt-to-Equity and Long-Term Debt/Eq Ratios - The Dwinnex
Quoin Pharmaceuticals CFO buys shares worth over $23,000 - Investing.com
Healthy Upside Potential: Quoin Pharmaceuticals Ltd ADR (QNRX) - SETE News
A closer look at QNRX’s price-to-free cash flow ratio - US Post News
Quoin Pharmaceuticals COO acquires $28,737 in company shares - Investing.com
Quoin Pharmaceuticals CEO acquires shares worth over $28k - Investing.com
Quoin Pharmaceuticals (NASDAQ:QNRX) Stock Quotes, Forecast and News Summary - Benzinga
QNRX Stock Hits 52-Week Low at $0.57 Amid Market Challenges - Investing.com Australia
symbol__ Stock Quote Price and Forecast - CNN
GLMD Stock Quote Price and Forecast - CNN
Earnings call: Quoin Pharmaceuticals reports Q4 progress and outlook By Investing.com - Investing.com South Africa
Major Indexes Muted Following Strong Jobs Report - Schaeffers Research
ADVFNFree stock and cryptocurrency prices, charts, market news and streaming real-time quotes. - ADVFN
Quoin Pharmaceuticals Ltd Adr Stock (QNRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.13%
0.37%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):